Loading news...
Adviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction value $71.01 million based on quarterly average price. The quarter-end value of position dropped by $65.05 million, reflecting both trading and Ocular Therapeutix share price changes.
BEDFORD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to three newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript
Shares of Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the fourteen research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to
Ocular Therapeutix (NASDAQ: OCUL) reported positive top-line results from its SOL-1 Phase 3 clinical trial evaluating AXPAXLI (also referred to as OTX-TKI) in wet age-related macular degeneration (wet AMD), highlighting sustained disease control, visual and anatomic outcomes, and a safety profile the company described as well tolerated. SOL-1 design and primary endpoint On the conference call,
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report)'s share price was up 9.5% during mid-day trading on Friday. The stock traded as high as $7.20 and last traded at $7.6970. Approximately 504,364 shares were traded during trading, a decline of 92% from the average daily volume of 6,703,719 shares. The stock had previously closed
San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigation focuses on Ocular's executive officers and whether investor losses may be recovered under federal securities laws.
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Ocular Therapeutix, Inc. (NASDAQ: OCUL). The investigation focuses on Ocular's executive officers and whether investor losses may be recovered under federal securities laws.
Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript
U.S. stock futures fluctuated on Tuesday following Friday's mixed close. Futures of major benchmark indices were mixed at the beginning of the holiday-shortened week as the markets were closed on Monday for Presidents' Day.
Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients maintain their vision compared to Regeneron's approved treatment Eylea in a late-stage trial.
BEDFORD, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced positive topline results from the SOL-1 Phase 3 superiority trial of AXPAXLI (also known as OTX-TKI), its investigational product candidate, for the treatment of wet age-related macular degeneration (AMD). After a loading phase, the SOL-1 trial compared a single dose of AXPAXLI (0.45 mg) to a single dose of aflibercept (2 mg) in patients with wet AMD. Under the pre-specified statistical analysis plan, which is aligned with the U.S. FDA in the SOL-1 Special Protocol Assessment (SPA) agreement, the superiority primary endpoint at Week 36 was met with high statistical significance (p=0.0006). In addition to achieving the primary endpoint, AXPAXLI showed either statistical significance or numerical superiority to aflibercept (2 mg) in key secondary and prespecified exploratory endpoints.
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will host a webcast to review the topline results of the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), on Tuesday, February 17, 2026.
BEDFORD, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to five newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report) saw some unusual options trading activity on Wednesday. Traders purchased 25,044 put options on the company. This represents an increase of 473% compared to the typical volume of 4,370 put options. Trending Headlines about Ocular Therapeutix Here are the key news stories impacting Ocular Therapeutix this week:
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.29 per share a year ago.
Ocular Therapeutix (OCUL) is a Strong Buy, driven by the pivotal SOL-1 Phase 3 trial for AXPAXLI™ in wet AMD, with topline results expected Q1 2026. AXPAXLI™ leverages proven science and a de-risked trial design, aiming to reduce injection frequency while maintaining vision, targeting a $10B+ market. Phase 1 data and masked SOL-1 observations suggest a high probability of meeting key endpoints, with minimal safety concerns to date.
BEDFORD, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to its newly appointed Global Chief Commercial Officer, David W. Robinson. The awards were approved by Ocular's Board of Directors and were made as inducements material to Mr. Robinson's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The biotechnology sector's strong fundamentals and robust innovation could continue to drive outperformance this year, according to Baird analysts. The firm noted that while macroeconomic risks such as rising interest rates remain, the biotechnology sector's underlying drivers are supportive.